Riccardo Paone

Riccardo Paone

Auto-generated profile, based on publicly available information

Riccardo Paone

Department of Genetics and Development, College of Physicians and Surgeons, Columbia University, New York, New York, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
MCMattia Capulli
Mattia Capulli
RPRiccardo Paone
Riccardo Paone
Nadia RucciNadia Rucci
Nadia Rucci

5 September 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MOMaría José Ortuño
María José Ortuño
SRSamuel T Robinson
Samuel T Robinson
PSPrakash Subramanyam
Prakash Subramanyam
RPRiccardo Paone
Riccardo Paone
YHYung-Yu Huang
Yung-Yu Huang
PDPatricia Ducy
Patricia Ducy
Long-term use of serotonin-reuptake inhibitors causes bone loss by acting centrally to counteract a peripheral, beneficial effect on bone. The use of selective serotonin-reuptake inhibitors (SSRIs) has been associated with an increased risk of bone fracture, raising concerns about their increasingly broader usage. This deleterious effect is poorly understood, and thus strategies to avoid this side effect remain elusive. We show here that fluoxetine (Flx), one of the most-prescribed SSRIs, acts on bone remodeling through two distinct mechanisms. Peripherally, Flx has anti-resorptive properties, directly impairing osteoclast differentiation and function through a serotonin-reuptake-independent mechanism that is dependent on intracellular Ca2+ levels and the transcription factor Nfatc1. With time, however, Flx also triggers a brain-serotonin-dependent rise in sympathetic output that increases bone resorption sufficiently to counteract its local anti-resorptive effect, thus leading to a net effect of impaired bone formation and bone loss. Accordingly, neutralizing this second mode of action through co-treatment with the β-blocker propranolol, while leaving the peripheral effect intact, prevents Flx-induced bone loss in mice. Hence, this study identifies a dual mode of action of SSRIs on bone remodeling and suggests a therapeutic strategy to block the deleterious effect on bone homeostasis from their chronic use.

19 July 2016 in Scientific Reports
Verified
Journal Article
Open access
VVVimal Veeriah
Vimal Veeriah
AZAngelo Zanniti
Angelo Zanniti
RPRiccardo Paone
Riccardo Paone
SCSuvro Chatterjee
Suvro Chatterjee
NRNadia Rucci
Nadia Rucci
MCMattia Capulli
Mattia Capulli
Endothelial cells are spatially close to osteoblasts and regulate osteogenesis. Moreover, they are sensitive to mechanical stimuli, therefore we hypothesized that they are implicated in the regulation of bone metabolism during unloading. Conditioned media from endothelial cells (EC-CM) subjected to simulated microgravity (0.08gand 0.008g) increased osteoblast proliferation and decreased their differentiation compared to unit gravity (1g) EC-CM. Microgravity-EC-CM increased the expression of osteoblastRankland subsequent osteoclastogenesis and induced the osteoblast de-differentiating factor, Lipocalin 2 (Lcn2), whose downregulation recovered osteoblast activity, decreasedRanklexpression and reduced osteoclastogenesis. Microgravity-EC-CM enhanced osteoblastNO-Synthase2 (NOS2) andCycloOXygenase2 (COX2) expression. Inhibition of NOS2 or NO signaling reduced osteoblast proliferation and rescued their differentiation. Nuclear translocation of the Lcn2/NOS2 transcription factor, NF-κB, occurred in microgravity-EC-CM-treated osteoblasts and in microgravity-treated endothelial cells, alongside high expression of the NF-κB activator, IL-1β. IL-1β depletion and NF-κB inhibition reduced osteoblast proliferation and rescued differentiation.Lcn2andNOS2were incremented inex vivocalvarias cultured in microgravity-EC-CM andin vivotibias and calvarias injected with microgravity-EC-CM. Furthermore, tibias of botulin A toxin-treated and tail-suspended mice, which featured unloading and decreased bone mass, showed higher expression ofIL-1β, Lcn2andNos2, suggesting their pathophysiologic involvement in endothelial cell-osteoblast crosstalk.

6 November 2014 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AKAruna Kode
Aruna Kode
AOArnaud Obri
Arnaud Obri
RPRiccardo Paone
Riccardo Paone
SKStavroula Kousteni
Stavroula Kousteni
PDPatricia Ducy
Patricia Ducy
GKGerard Karsenty
Gerard Karsenty

1 April 2015 in Biomaterials
Verified
Journal Article
Open access
ACAlfredo Cappariello
Alfredo Cappariello
RPRiccardo Paone
Riccardo Paone
AMAntonio Maurizi
Antonio Maurizi
MCMattia Capulli
Mattia Capulli
Nadia RucciNadia Rucci
Nadia Rucci
Anna Maria TetiAnna Maria Teti
Anna Maria Teti
Deficiency of Receptor Activator of NF-κB Ligand (RANKL) prevents osteoclast formation causing osteopetrosis. RANKL is a membrane-bound protein cleaved into active soluble (s)RANKL by metalloproteinase 14 (MMP14). We created a bio-device that harbors primary osteoblasts, cultured on 3D hydroxyapatite scaffolds carrying immobilized MMP14 catalytic domain. Scaffolds were sealed in diffusion chambers and implanted in RANKL-deficient mice. Mice received 1 or 2 diffusion chambers, once or twice and were sacrificed after 1 or 2 months from implants. A progressive increase of body weight was observed in the implanted groups. Histological sections of tibias of non-implanted mice were negative for the osteoclast marker Tartrate-Resistant Acid Phosphatase (TRAcP), consistent with the lack of osteoclasts. In contrast, tibias excised from implanted mice showed TRAcP-positive cells in the bone marrow and on the bone surface, these latter morphologically similar to mature osteoclasts. In mice implanted with 4 diffusion chambers total, we noted the highest number and size of TRAcP-positive cells, with quantifiable eroded bone surface and significant reduction of trabecular bone volume. These data demonstrate that our bio-device delivers effective sRANKL, inducing osteoclastogenesis in RANKL-deficient mice, supporting the feasibility of an innovative experimental strategy to treat systemic cytokine deficiencies.

1 October 2014 in Molecular Metabolism
Verified
Journal Article
Open access
DKDaisuke Kajimura
Daisuke Kajimura
RPRiccardo Paone
Riccardo Paone
JMJ. John Mann
J. John Mann
GKGerard Karsenty
Gerard Karsenty
The transcription factor FoxO1 regulates multiple physiological processes. Here, we show that FoxO1 is highly expressed in neurons of the locus coeruleus and of various sympathetic ganglions, but not in the adrenal medulla. Consistent with this pattern of expression, mice lacking FoxO1 only in sympathetic neurons (FoxO1 Dbh-/-) display a low sympathetic tone without modification of the catecholamine content in the adrenal medulla. As a result, FoxO1 Dbh-/- mice demonstrate an increased insulin secretion, improved glucose tolerance, low energy expenditure, and high bone mass. FoxO1 favors catecholamine synthesis because it is a potent regulator of the expression of Dbh that encodes the initial and rate-limiting enzyme in the synthesis of these neurotransmitters. By identifying FoxO1 as a transcriptional regulator of the sympathetic tone, these results advance our understanding of the control of some aspects of metabolism and of bone mass accrual.